Son Shine Awards - Duchenne Foundation

Son Shine Awards - Duchenne Foundation: "The ‘SonShine’ Achievement Awards are designed specifically to celebrate the achievements and strengths of boys with Duchenne muscular dystrophy. "

Duchenne Foundation

Duchenne Foundation: "Duchenne Foundation, the only
national non-profit specifically for Australian families affected
by Duchenne muscular dystrophy."

We need YOUR help to further our Advocacy efforts in Washington, DC

Google Reader (27): "We need YOUR help to further our Advocacy efforts in Washington, DC!"

How can YOU help? We need you to make a phone call and send an email!

ACTION 1. Phone Call: Please take a moment to CALL your Senators and Representatives and urge them to sign onto our multimember letter being circulated by Representative Matsui in the House and Senators Wicker in the Senate.

Wondering what to say when you call your Senators and Congressman?

Dont worry, we have provided you with a script: Senate Phone Script House Phone Script

To look up their phone number click here

ACTION 2. Send Action Alert NOW: Email your Representative and Senators-PPMD is requesting your support by clicking through our email action alert below. It takes two minutes!

This simple one step alert will automatically send our message to your Senators and Representative and will also allow you to forward the message to friends and family who may also want to support our Advocacy Agenda.

Click here to send an email to your members of Congress!

Research Review No. 28 Some new Drugs. - Karl2346 - Stopwasting - Action Duchenne - Fighting for a cure for muscular dystrophy - Suramin

Research Review No. 28 Some new Drugs. - Karl2346 - Stopwasting - Action Duchenne - Fighting for a cure for muscular dystrophy: "Survival curves are plotted in the paper and they clearly show that being given bisphosphanates was “associated with a significant improvement in survival rate (P =.005, log-rank test).” They conclude with the sentence: “The treatment of patients with DMD with steroids and bisphosphonates seems to be associated with significantly improved survival compared with treatment with steroids alone.” This study on humans rather than mice should be taken very seriously as increased survival of years is recorded in this study."

Parent Project Muscular Dystrophy: 2011 Advocacy Conference & One Voice Summit

Parent Project Muscular Dystrophy: 2011 Advocacy Conference & One Voice Summit: "Parent Project Muscular Dystrophy Marks 10 Years of Advocacy
with One Voice Advocacy Summit"

Action Duchenne Love Runs – there’s still time to register and be officially timed - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Action Duchenne Love Runs – there’s still time to register and be officially timed - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "ACTION DUCHENNE LOVE RUNS – THERE’S STILL TIME TO REGISTER AND BE OFFICIALLY TIMED"

Come and enjoy a drinks reception at Whickham Villa Health Club featuring Action Duchenne’s “Life Thru a Lens” photographic exhibition and ground-breaking film - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Come and enjoy a drinks reception at Whickham Villa Health Club featuring Action Duchenne’s “Life Thru a Lens” photographic exhibition and ground-breaking film - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: "COME AND ENJOY A DRINKS RECEPTION AT WHICKHAM VILLA HEALTH CLUB FEATURING ACTION DUCHENNE’S “LIFE THRU A LENS” PHOTOGRAPHIC EXHIBITION AND GROUND-BREAKING"

Lack of DOT1L enzyme could lead to some types of heart disease: Study

Lack of DOT1L enzyme could lead to some types of heart disease: Study: "Everyone knows chocolate is critical to a happy Valentine's Day. Now scientists are one step closer to knowing what makes a heart happy the rest of the year."

GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication

GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication: "GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (`968), in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III."